内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Lancet：2型糖尿病治疗，礼来tirzepatide临床击败“网红降糖药”索马鲁肽！

2021-08-14 MedSci原创 MedSci原创

达格列净索马鲁特
关注

在2型糖尿病患者中，tirzepatide优于胰岛素，在第52周时HbA1c和体重的降低幅度更大，低血糖风险更低。

2型糖尿病（T2DM）是一种代谢紊乱，机体对胰岛素不敏感，出现高血糖症状。Tirzepatide是最近最受瞩目的新型降糖药之一，它是一种每周注射一次的GIP和GLP-1受体双重激动剂，可将两种肠促胰岛素的作用整合到一个分子中，代表治疗2型糖尿病的一类新手段。 GIP是一种激素，可能补充GLP-1受体激动剂的作用。在临床前模型中，已证明GIP可减少摄食量并增加能量消耗，因此导致体重减轻，当与GLP-1受体激动剂联合使用时，可能对葡萄糖水平和体重产生更大影响。 2021年3月4日，礼来公布了进行40周的3期临床试验SURPASS-2结果，数据显示，与诺和诺德1毫克注射用semaglutide（索马鲁肽）相比，三种剂量的tirzepatide均能使成人II型糖尿病患者的糖化血红蛋白和体重从基线水平显著降低。 近期，为了评估tirzepatide与滴定胰岛素相比，适用于使用或不使用SGLT2抑制剂的二甲双胍控制不佳的2型糖尿病患者的疗效和安全性，来自奥地利第一医学部和卡尔-兰德斯坦纳肥胖症和代谢紊乱研究所开展了相关研究，结果发表在Lancet杂志上。 在这项开放标签、平行分组、多中心（122个

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-04-25 病毒猎手

    #泰瑞帕肽#大于#索马鲁肽#，更大于#利拉鲁肽#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-10-21 未来将来

    新的方法，新的起点

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-05-13 howi

    #Lancet#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-01-17 zhanglin3079

    #糖尿病治疗#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 minlingfeng

    #降糖药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 caoliehu

    #网红#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-16 gwc384

    #EPA#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 goodbing

    顶刊就是不一样，质量很高，内容精彩！学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1214247, encodeId=91fa121424e06, content=<a href='/topic/show?id=16b6104504ef' target=_blank style='color:#2F92EE;'>#泰瑞帕肽#</a>大于<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>，更大于<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104504, encryptionId=16b6104504ef, topicName=泰瑞帕肽), TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:19:18 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062655, encodeId=1e9c1062655ef, content=新的方法，新的起点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Oct 21 17:31:07 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831273, encodeId=8b7518312e3c5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri May 13 22:38:42 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990000, encodeId=b15f19900006b, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Jan 17 02:38:42 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270929, encodeId=ec5412e0929c6, content=<a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98179, encryptionId=4066981e99e, topicName=降糖药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404244, encodeId=feb0140424436, content=<a href='/topic/show?id=ff77e94785a' target=_blank style='color:#2F92EE;'>#网红#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79478, encryptionId=ff77e94785a, topicName=网红)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981e2448917, createdName=caoliehu, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427544, encodeId=99fb142e544cb, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Aug 16 09:38:42 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034423, encodeId=b606103442359, content=顶刊就是不一样，质量很高，内容精彩！学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043734, encodeId=f3221043e3420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Aug 14 21:38:42 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007906, encodeId=fad9100e906ab, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b3545492917, createdName=smart Ren, createdTime=Sat Aug 14 20:13:10 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 smart Ren

    学习学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Eur J Heart Fail：达格列净对射血分数降低的心衰患者贫血的影响

达格列净是否有助于改善心力衰竭患者的贫血症状？

JASN：达格列净对4期慢性肾脏病的影响

在4期CKD和蛋白尿患者中，达格列净的益处与DAPA-CKD试验中观察到的总体益处一致，没有证据表明其风险增加。

Circulation：达格列净治疗对HFrEF患者肾功能和预后的效益

很多射血分数降低的心衰患者（HFrEF）都存在慢性肾病，使药物管理复杂化、预后不良。本文评估了达格列净对HFrEF患者（根据基础肾功能）的安全性和疗效，同时评估达格列净对肾功能的影响。

Circulation：达格列净可明显改善慢性肾病患者的多种不良预后结局！

本研究评估这些患者发生心血管和肾脏事件的相对风险，以及达格列净对这两种事件的影响，并根据有无心血管疾病进行分层。

Lancet Diabetes Endocrinol：达格列净可否改善有心脏代谢风险因素的新冠肺炎患者的临床预后？

SGLT2抑制剂达格列净对心脏和肾脏具有显著的保护作用，是否能改善有心脏代谢风险因素的新冠肺炎患者的临床预后？

Journal of the American Society of Nephrology：达格列净对晚期肾病患者有效且安全

之前发表在circulation上的一项研究表明达格列净可降低慢性心肾病患者（无论有无合并2型糖尿病）的肾衰、心血管性死亡或心衰住院的风险，延长其存活期，且不受有无合并心血管疾病的影响。那达格列净对4

拓展阅读

PLoS One：伴和不伴有糖尿病的腕管综合征患者的手术次数有差别吗?

糖尿病患者比非糖尿病患者更多接受手术治疗CTS。并且1型糖尿病患者多于2型糖尿病患者。

Int J Gen Med：中国乳腺癌妇女糖尿病和前驱糖尿病糖化血红蛋白诊断的最佳截断值

在中国无糖尿病史的乳腺癌妇女中，未确诊糖尿病的患病率很高。在中国乳腺癌女性中，HbA1c诊断糖尿病和前驱糖尿病的最佳临界值分别为6.0%和5.5%。

Narrative：糖尿病患者的围术期管理策略

对于糖尿病患者这一高风险群体的围术期管理，我们要合理的进行围术期干预和预防。

世界首例自体再生胰岛移植成功，胰岛素依赖型糖尿病治疗获得突破性进展

国际上首次利用诱导多能干细胞（iPS细胞/iPSC）来源的自体再生胰岛移植，成功治愈胰岛功能严重受损糖尿病的病例报道。

降糖降血脂+减重超28斤；司美格鲁肽可减肥还能治心衰 | 糖尿病前沿荟萃

《医学新视点》持续关注糖尿病领域研究进展，梳理了2024年1月~4月全球权威期刊（IF≥10）发表的507篇糖尿病领域研究。

李平平团队《自然·通讯》：发现巨噬细胞分泌的Galectin-3抑制胰岛素分泌

该研究发现了炎症诱导糖尿病胰岛细胞功能障碍的新机制，为改善细胞功能的药物研发提供新靶点和新策略。